Types and importance of human papilloma virus vaccine and methods in promoting it for cervical cancer prevention
Authors: Dahab Amaal Abdo , Dream Saeed Mohammed , Mokli Bandar Ibrahim , Alkhawaji Ahmed Ibrahim , Shebaily Rami Ali , Andijani Nawaf Khalid , Ibrahim Zakia Isam , Alhasoun Saud Abdullah , Alsufyani Raghad Ali , Jowharji Tala Wajdi , Abdulrahim Baraa Abdulrhman 
Published: November 2022

Cervical cancer continues to be a significant global challenge as it is the fourth major cause of mortality among women. Cervical cancer is primarily caused by repeated human papilloma virus (HPV) infections. Although the incidence and death of cervical cancer have declined in high-income nations, the disease still places a heavy burden on low- and middle-income countries. HPV-16Cervical cancer continues to be a significant global challenge as it is the fourth major cause of mortality among women. Cervical cancer is primarily caused by repeated human papilloma virus (HPV) infections. Although the incidence and death of cervical cancer have declined in high-income nations, the disease still places a heavy burden on low- and middle-income countries. HPV-16 is responsible for 50% while HPV-18 is responsible for 10% of cervical cancer cases. The introduction of HPV vaccines is limited in developing areas with greater need, despite the fact that they offer a potential alternative for disease control. The purpose of this research is to review the available information about types and importance of HPV vaccine and methods in promoting it for cervical cancer prevention. Three HPV vaccines for prevention of cervical cancer are available including a quadrivalent vaccine that protects against 4 HPV types, and the second is a bivalent vaccine that protects against 2 high-risk oncogenic HPV types and third is a 9-valent vaccine. All three vaccines provide comparable coverage. Preventative vaccinations against the virus, given to women before HPV infection, have proven to be efficient and have the potential to reduce the incidence of cervical cancer. Thus, it is advised to immunize girls aged 9-14 years. The development of the HPV vaccine has made primary cervical cancer prevention possible. Health promotion and education can potentially contribute to increasing the awareness of community regarding cervical cancer prevention and can lead to better utilization of HPV vaccine.is responsible for 50% while HPV-18 is responsible for 10% of cervical cancer cases. The introduction of HPV vaccines is limited in developing areas with greater need, despite the fact that they offer a potential alternative for disease control. The purpose of this research is to review the available information about types and importance of HPV vaccine and methods in promoting it for cervical cancer prevention. Three HPV vaccines for prevention of cervical cancer are available including a quadrivalent vaccine that protects against 4 HPV types, and the second is a bivalent vaccine that protects against 2 high-risk oncogenic HPV types and third is a 9-valent vaccine. All three vaccines provide comparable coverage. Preventative vaccinations against the virus, given to women before HPV infection, have proven to be efficient and have the potential to reduce the incidence of cervical cancer. Thus, it is advised to immunize girls aged 9-14 years. The development of the HPV vaccine has made primary cervical cancer prevention possible. Health promotion and education can potentially contribute to increasing the awareness of community regarding cervical cancer prevention and can lead to better utilization of HPV vaccine.